Biolinerx Ltd. and MD Anderson Cancer Center signed collaboration agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BIOLINERX LTD. announced the signing of a collaboration agreement with MD Anderson Cancer Center for the investigation of BL-8040 in combination with Keytruda (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login